Roche reports a strong start to the year and, consequently, upgrades the 2019 guidance. Q1 sales grew by 8% at CER with the growth coming predominantly from the pharma business (+10) as diagnostics (+1%) languished (an unpleasant surprise). The new drugs continued to strengthen, amid biosimilar competition for the legacy ones in Europe and ahead of the threat in the US. The outlook for both revenue and core earnings for the year has been raised.
18 Apr 2019
New drugs mightier than the bio-similar erosion
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New drugs mightier than the bio-similar erosion
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
18 Apr 2019 -
Author:
Kamla Singh -
Pages:
3
Roche reports a strong start to the year and, consequently, upgrades the 2019 guidance. Q1 sales grew by 8% at CER with the growth coming predominantly from the pharma business (+10) as diagnostics (+1%) languished (an unpleasant surprise). The new drugs continued to strengthen, amid biosimilar competition for the legacy ones in Europe and ahead of the threat in the US. The outlook for both revenue and core earnings for the year has been raised.